Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
TSI EDITOR |
2022-05-19
Novamind announces the full-scale launch of Frontline KAP, group-based ketamine-assisted therapy for frontline healthcare workers suffering from burnout/stress/trauma, at select clinic locations.
TSI EDITOR |
2022-05-19
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
TSI EDITOR |
2022-05-19
MindMed announces positive safety and tolerability results from its Phase 1 clinical trial of MM-110 (18-MC) as a treatment for opioid withdrawal.
TSI EDITOR |
2022-05-19
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
TSI EDITOR |
2022-05-16
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
TSI EDITOR |
2022-05-17
Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.
TSI EDITOR |
2022-05-17
Cybin Inc announces that it will take part in the NYSE's "morning bell" ceremony for the May 18th trading session.
TSI EDITOR |
2022-05-17
Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.
TSI EDITOR |
2022-05-17
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
TSI EDITOR |
2022-05-16
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now